𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Specific chromosomal mutagenesis observed in stimulated lymphocytes from patients with S-ANLL

✍ Scribed by Zissis Mamuris; Jeanine Dumont; Bernard Dutrillaux; Alain Aurias


Publisher
John Wiley and Sons
Year
1990
Tongue
French
Weight
670 KB
Volume
46
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


An analysis of R-banded PHA-stimulated lymphocytes from I 3 patients with secondary acute non-lymphocytic leukemia (S-ANLL) following breast cancer or lymphoma, and treatment by alkylating agents and/or radiotherapy, is reported. We found that chromosomes 5,7, I I and I 7 are over-involved in structural rearrangements. These anomalies are similar to those observed in the same categories of patients without S-ANLL, and after in vitro treatment of normal lymphocytes by the alkylating agent melphalan. These anomalies are thus likely to be induced by treatment, independently of S-ANLL. However, the same chromosomes (5,7, I I and 17) are recurrently deficient in leukemic S-ANLL clones. In spite of these similarities, it remains unlikely that the deficiencies observed in leukemic clones were directly induced at the time of treatment. Probably, treatment of primary cancers induces nonrandom mutations of recessive genes located on these chromosomes as also indicated by chromosomal lesions. Various rearrangements including deletions of the homologous normal counterparts may then occur, unmasking mutated recessive genes. The latter stage would be concomitant with the leukemogenic process.


📜 SIMILAR VOLUMES


Tumor-specific CD8+ T lymphocytes derive
✍ Franck Housseau; Daniel A. Langer; Samuel D. Oberholtzer; Anitha Moorthy; Hyam I 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 150 KB 👁 2 views

## Abstract To identify tumor‐associated antigens as putative targets for developing immunotherapies against prostate cancer, we investigated the ability of T cells derived from the peripheral blood lymphocytes of prostate cancer patients to recognize autologous tumor cells. The technical challenge